Recruiting

Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.

This is multicentric, spontaneous, observational, retrospective and prospective study.

I'm interested View official listing
ClinicalTrials.gov IDNCT05817227
PhaseNot Applicable
Enrollment300
SponsorNational Cancer Institute, Naples
Age18 Years and older
SexFEMALE
I'm interested View official listing

Conditions studied

Breast Cancer

About this study

This is multicentric, spontaneous, observational, retrospective and prospective study.

Primary outcomes

Eligibility information

Inclusion Criteria: * TNBC breast cancer patients, before any drug treatment * healthy women aged 25-60 Exclusion Criteria: * donors suffering from diabetes, hypertension, active infectious states, HIV infection, Hepatitis B or C, chronic inflammatory diseases, current or previous neoplasms, heart disease or drug treatment.

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-19.